Poly Medicure Q1 FY27 results: revenue up 12% standalone, 30% consolidated
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure reported Q1 FY27 (quarter ended June 30, 2026) results. Standalone revenue from operations rose 12.2% YoY to Rs 431.1 cr; PAT was nearly flat at Rs 88.1 cr vs Rs 87.9 cr. Consolidated revenue jumped 30.3% YoY to Rs 525.4 cr, but PAT dipped 8.4% to Rs 85.3 cr. Basic EPS was Rs 8.69 standalone and Rs 8.49 consolidated. Board granted 1,476 ESOP options and allotted 1,975 shares under ESOP 2020, re-appointed cost auditors, and noted Deputy CS Ravi Prakash resignation effective Aug 10, 2026. Acquired Brazil unit Medyneo and consolidated Himalayan Mineral Waters.
Strong consolidated revenue growth signals expansion, but mild PAT dip on consolidation costs. ESOP grants and KMP exit are routine.